Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV).
DTaP-wIPV
PT antibody
pertussis
poliovirus
Journal
Japanese journal of infectious diseases
ISSN: 1884-2836
Titre abrégé: Jpn J Infect Dis
Pays: Japan
ID NLM: 100893704
Informations de publication
Date de publication:
23 Jan 2019
23 Jan 2019
Historique:
pubmed:
2
11
2018
medline:
10
9
2019
entrez:
2
11
2018
Statut:
ppublish
Résumé
A follow-up serological study was conducted involving 47 subjects who received 4 doses of diphtheria and tetanus toxoids, combined with the acellular pertussis vaccine (DTaP) together with Salk-type inactivated polio vaccine (DTaP-wIPV), until 6 years of age. All antibody levels declined more rapidly than expected within 3 years after the completion of primary vaccination with the 4th booster dose, and titers persisted until 6 years of age. The positive rate of the IgG antibody against pertussis toxin (PT) was 31.9% (15/47) at 4 years of age, 41.0% (16/39) at 5 years of age, and 40.5% (15/37) at 6 years of age. A significant increase in anti-PT antibodies was observed in 6 subjects, suggesting subclinical infection. Positive rates of antibodies against other targets did not decrease; however, titers of neutralizing antibodies against poliovirus type III decreased in a few subjects. These data suggest the need for an additional preschool booster immunization using DTaP-wIPV.
Identifiants
pubmed: 30381690
doi: 10.7883/yoken.JJID.2018.314
doi:
Substances chimiques
Antibodies, Bacterial
0
Antibodies, Viral
0
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Poliovirus Vaccine, Inactivated
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM